Equivalent physical dose (EPD) for improved precision in voxelized dosimetry

Elliot M. Abbott, DPhil (Oxon)[1]

elliot.abbott@gmail.com

[1]Integrated Cancer Research Foundation

Abstract

Equivalent dose in 2 Gy fractions (EQD2) has long been considered the more practical alternative to biological effective dose (BED) for the clinic. However, the basic mathematics of EQD2 are debated. In this paper, by a simple proof of plugging the EQD2 dose into the BED equation and getting a different result, it is demonstrated that the standard EQD2 equation is mathematically inconsistent. The mathematically exact derivation, referred to here as equivalent physical dose (EPD), which solves for the roots of the quadratic equation, is provided and compared against the existing derivation, which separates the Relative Effect term from the BED equation. Additionally, the EQD2 expression is applied assuming a heterogeneous dose, which has become inappropriate in the era of voxelized dosimetry where a voxel in the structure, like organs at risk, may have a differing dose from the prescription. The implications of the >10% errors introduced from the existing formulations are explored and could explain the reported failings of EQD2 in the hypofractionation, serial organ irradiation, and dose accumulation contexts. This work provides an explanation to confusing aspects about how to apply radiobiology models, which have limited its development. Optimizing therapy around biological dimensions (as conformal radiotherapy did for spatial dimensions) could provide vital flexibility to radiotherapy treatment planning.

Introduction

Absorbed dose is known to explain clinical outcomes from radiation therapy. However, correction factors were added to explain secondary effects like tissue radiosensitivity and repair. Radiation oncologists and medical physicists often use biological effective dose (BED) in the clinic to convert between different fractionation schemes or treatment modalities to adjust for when a patient wants to take their dream vacation or benefits from multiple courses of therapy.

Significant clinical progress with radiobiology started with the advent of the linear-quadratic (LQ) model.[1] The LQ model defines the probability of inactivating cells as a function of radiation dose, i.e. the surviving fraction (SF) given by $SF = e^{-(\alpha D + \beta D^2/n)}$ where α and β are radiosensitivity coefficients, D is absorbed dose, and n is the number of fractions. The SF could be applied to both experimental and clinical data and was used to formulate the common definition for BED used today ($BED \equiv \frac{\ln SF}{-\alpha}$). The idea of dividing the SF by -α made radiobiological considerations simple enough to implement in the clinic based on a single parameter, the α/β ratio, i.e. $BED = D \times (1 + \frac{D/n}{(\alpha/\beta)})$.[1] For this reason, BED has been a valuable tool for improving the quality of patient outcomes over the past decades.

When working outside of the conventional 2-Gy fractionation schedule of external beam photon therapy, such as hypofractionated therapy at 5 Gy per fraction, it is most helpful to convert the delivered BEDs into the same physical dose terms as 2 Gy fractions as this is a treatment schedule of greatest familiarity to the radiation therapy team.[2] The existing methods are prolifically documented in the literature and rely on the concept known as equivalent dose (EQD). EQD is defined as the equivalent dose of therapy in terms of biological effects. EQD is commonly derived by dividing equated BED models by a "relative effect" (RE) term $RE = (1 + \frac{d}{\alpha/\beta})$ from the LQ model, where d is the reference dose per fraction (Appendix A). This derivation yields the following general formula $EQD = \frac{BED}{1 + \frac{d}{\alpha/\beta}}$, which is recommended by the Report Committee 25 of the International Commission on Radiation Units & Measurements (ICRU).[3]

The radiation oncology field conventionally simplifies EQD in terms of 2 Gy fractions (EQD2) by substituting d=2 for 2 Gy fractions into the general EQD equation such that

---

[1] Note, D/n is intentionally used here for dose per fraction instead of d to emphasize that the total dose information D, unlike the quoted reference dose per fraction, is directly used in the voxelized dose distribution when performing treatment planning.

$EQD2 = \frac{BED}{1+\frac{2}{\alpha/\beta}}$ (Equation 1).[2] Note that the EQD2 formula may also appear as $EQD2 = D \times \frac{D/n+\alpha/\beta}{2+\alpha/\beta}$, which is the same quantity reduced with the numerator and denominator multiplied by α/β. EQD2 is the most widely used tool to account for variations in treatment schedules and is accurate when comparing dose prescriptions.

However, this article will demonstrate that there are critical issues with these popular expressions of EQD2 in their most widely used forms, and especially when it comes to voxelized dosimetry, which can lead to dose evaluation inaccuracies in excess of 10%. This article makes two independent claims and proves that both the EQD2 and general EQD expressions contain critical issues.

- **Claim 1:** The EQD2 expression makes an assumption that exactly the full prescription dose is homogeneously delivered to all tissues, which should particularly not apply to organs at risk (OARs).
- **Claim 2:** EQD is derived mathematically non-invertibly from the LQ model, which introduces systematic error in terms of isoeffect and sows confusion into the dose–effect principles of radiation biology.

To address the above claims, this article provides the alternative equivalent dose formulation (referred to as "equivalent physical dose (EPD)" here), proves the claims both analytically and numerically, and finally demonstrates the quantitative impact of the existing systematic errors.

Methods

Claim 1 Proof that EQD2 does not apply to heterogeneous dose

Often seen in therapies like high dose-rate (HDR) or low dose-rate (LDR) brachytherapy, ^{90}Y selective internal radiotherapy (SIRT), and iodine-131 or other molecular radiotherapy (MRT), where a radioactive source is placed directly inside the body, the radiation dose distribution is heterogeneous, with hot and cold spots. Similarly, in external beam radiotherapy (EBRT), techniques like LATTICE and GRID therapies intentionally implement heterogeneous dose distribution to take advantage of bystander/abscopal effects and immune response in order to help with absorbed dose constraints. In conventional EBRT, there are also some voxels in a planning target volume (PTV) that may not have achieved the target dose constraints in the optimizer.

Despite the known heterogeneity of some dose distributions, the standard equation 1 formula for EQD2 assumes homogeneity, which does not apply for tissues everywhere.

These heterogeneous areas should not calculate EQD with the standard EQD2 formula $EQD2 = \frac{BED}{1+\frac{2}{\alpha/\beta}} = D \times \frac{D/n+\alpha/\beta}{2+\alpha/\beta}$. Having the "2" fixed in the equation assumes the tumor volume received a uniform "prescription dose", which introduces a bias for real-world voxelized situations. In reality, each voxel receives a dose, which carries localized biological implications for response and toxicity.

Importantly, fixing 2 Gy per fraction neglects the fact that the full prescription dose is not delivered to normal tissues. Because normal tissues absorb doses much less than the prescribed dose per fraction of 2 Gy, the risk of normal tissue complication is not adequately considered when 2 Gy is fixed in the denominator. Furthermore, the only limitation to the maximum amount of dose that can be delivered is normal tissue dose (we would give thousands of Gy to the tumor if not for risk to normal tissues), so one should worry more about the accuracy of equivalent dose to normal tissue, which the standard EQD2 model does not consider.

Claim 2 Proof that EQD is mathematically inconsistent

The classical derivation[4] for EQD is given in Appendix A. However, this derivation separates the dose and relative effect (RE), which diminishes the functionality of the LQ model. Because relative effect is dependent on dose, this results in incompletely solving the equation for D. Separating dose D from the RE term effectively asserts a new equation (EQD=D) substituted only in the non-RE term whereas it should simply be solving the complete equation directly for D. Critically, this means that the expression for EQD2 is not-invertible.

The derivation of EPD, which is an invertable formulation, is given in Appendix B. Note that this formulation is not new and has been comparably presented in equation 11 by Fowler[5] in terms of dose-per-fraction side-by-side with the voxelwise-inapplicable EQD definition.

Error analysis

The discrepancy introduced by the standard EQD approach may introduce errors. Here, this is quantitatively defined by taking the $error = 100\% \times \frac{EQD-EPD}{EPD}$.

Results

Biologically equivalent treatment regimens with equivalent prescribed BED were chosen for use in sample calculations. Table 1 offers a comparison of sample calculations using the equivalent dose expressions based on these regimens.

Note that a hypothetical neighboring voxel receiving only 75% of the full prescription (Rx) dose receives 1.5 Gy/fraction for the same treatment. While this non-conformity is subject to intra-plan variability largely outside the control of a therapy team, the number of fractions scheduled is a factor that may be controlled exactly. Depending on the uniformity of deposited dose, the non conforming voxels can make up the majority of the data.

In Table 1, box A, the prescription voxel is exactly correct for all formulations of equivalent dose because they equal D_{Rx}. The fact that all of these formulations yield the same correct result underscores the confusion about the generalizability of BED modelling. In box B, the prescription voxel is exactly correct for the EQD2 formulation but inexact for the revised EQD2 formulation by 11%. In box C, the non-conforming voxel is inexact for the conventional EQD2 formulation by -12.5% but exactly correct for the revised EQD2 formulation. Finally, the non-conforming voxel is inexact for the conventional EQD2 by -13.3% and inexact for the revised EQD2 by 8.4%.

Table 1: *Sample calculations comparing (1) EQD2, (2) revised EQD2, and (3) EPD calculation method per claim 1: Treatments A and B are biologically equivalent but have differing prescription dose and number of fractions. The combinations here compare a prescription voxel (achieving the desired prescription dose of 60 Gy) with a real voxel (achieving 75% of the prescription dose). This only works for the prescription voxel because of the underlying assumptions. BED for the nonconforming voxel is calculated separately from the treatment prescription BED because that voxel is absorbing a different dose of radiation from the prescription.*

See reference equations in Appendix C Assume $\alpha/\beta = 2\,Gy$	**Treatment A** (30 fractions at 2 Gy/fraction) Prescription dose of $D_{Rx} = 60\,Gy$ $n_2 = 30$	**Treatment B** (16 fractions at 3 Gy/fraction) Prescription dose of $D_{Rx} = 48\,Gy$
Prescription voxel D_{Rx}	$D_{Rx} = 60\,Gy$ $D_{Rx}/n = 2\,Gy/fraction$ $BED_{Rx} = 60\,Gy\,(1 + \frac{60\,Gy/30}{2\,Gy}) = 120\,Gy$ **[A]** $EQD2_{Rx} = \frac{120\,Gy}{1 + \frac{2\,Gy}{2\,Gy}} = 60\,Gy = D_{Rx}$ $^{revised}EQD2_{Rx} = \frac{120\,Gy}{1 + \frac{(2\,Gy \times 30)/30}{2\,Gy}} = 60\,Gy = D_{Rx}$ $EPD2 = 30\frac{2\,Gy}{2}\,[\sqrt{1 + \frac{4(120\,Gy)}{30(2\,Gy)}} - 1] = 60\,Gy = D_{Rx}$	$D_{Rx} = 48\,Gy$ $D_{Rx}/n = 3\,Gy/fraction$ $BED_{Rx} = 48\,Gy\,(1 + \frac{48\,Gy/16}{2\,Gy}) = 120\,Gy$ **[B]** $EQD2_{Rx} = \frac{120\,Gy}{1 + \frac{2\,Gy}{2\,Gy}} = 60\,Gy = D_{Rx}$ $^{revised}EQD2_{Rx} = \frac{120\,Gy}{1 + \frac{(3\,Gy \times 16)/30}{2\,Gy}} = 66.67\,Gy \neq D_{Rx}$ $EPD2 = 30\frac{2\,Gy}{2}\,[\sqrt{1 + \frac{4(120\,Gy)}{30(2\,Gy)}} - 1] = 60\,Gy = D_{Rx}$
Non-conforming voxel $D_{nc} = 75\% \cdot D_{Rx}$	$D_{nc} = 0.75 D_{Rx} = 0.75 \cdot 60\,Gy = 45\,Gy$ $D_{nc}/n = 1.5\,Gy/fraction$ $BED_{nc} = 45\,Gy\,(1 + \frac{45\,Gy/30}{2\,Gy}) = 78.75\,Gy$ **[C]** $EQD2_{nc} = \frac{78.75\,Gy}{1 + \frac{2\,Gy}{2\,Gy}} = 39.375\,Gy \neq D_{nc}$ $^{revised}EQD2_{nc} = \frac{78.75\,Gy}{1 + \frac{(1.5\,Gy \times 30)/30}{2\,Gy}} = 45\,Gy = D_{nc}$ $EPD2 = 30\frac{2\,Gy}{2}\,[\sqrt{1 + \frac{4(78.75\,Gy)}{30(2\,Gy)}} - 1] = 45 = D_{nc}$	$D_{nc} = 0.75 D_{Rx} = 0.75 \times 48\,Gy = 36\,Gy$ $D_{nc}/n = 2.25\,Gy/fraction$ $BED_{nc} = 36\,Gy\,(1 + \frac{36\,Gy/16}{2\,Gy}) = 76.5\,Gy$ $EQD2_{nc} = \frac{76.5\,Gy}{1 + \frac{2\,Gy}{2\,Gy}} = 38.25\,Gy$ $^{revised}EQD2_{nc} = \frac{76.5\,Gy}{1 + \frac{(2.25\,Gy \times 16)/30}{2\,Gy}} = 47.8125\,Gy$ $EPD2 = 30\frac{2\,Gy}{2}\,[\sqrt{1 + \frac{4(76.5\,Gy)}{30(2\,Gy)}} - 1] = 44.09453421\,Gy$

Because Treatment A is given at 2 Gy/fraction, the method can be directly validated by comparing the voxel's calculated equivalent dose with its original physical dose. The equivalent dose for Treatment A (2 Gy/fraction) using EQDx is exact for the voxel receiving exactly the prescription dose. However, for a dose not conforming to the exact prescription dose, systematic errors of the EQDx method of approximately 10% are demonstrated. However, it is possible this EQD modelling introduces much higher in excess of 50% given the set of relevant parameters and doses involved.

In Figures 1 and 2, these equivalent dose calculation errors introduced in Table 1 are explored. Figure 1 illustrates a delivered dose and equivalent dose calculation deviating from the prescription dose for regimens of (A) the same dose per fraction per Treatment A and (B) different dose per fraction per Treatment B. Figure 2 plots the errors shown in Figure 1 as a function of dose to demonstrate the limitations of the EQD2 model.

Figure 1: EQD2 calculations performed for two different biologically-equivalent treatment schedules such that the prescription BED=120 Gy. (A) Treatment A delivered 60 Gy in 30 fractions. All equivalent dose equations compute the same EQD2 value of 60 Gy at the Rx dose as expected because this was delivered in 2 Gy fractions. The conventional EQD2 equation deviates from identity and therefore incorporates error for non-uniform doses in the treatment volume. The revised EQD2 and EPD equations have a slope of 1 as they should since the regimen is already 2 Gy/fraction. (B) Treatment B delivered 48 Gy in 16 fractions. Only the EPD equation returns the expected biological equivalent Rx dose for the 2 Gy per fraction schedule.

Figure 2: Error introduced from the formulations of EQD2 relative to the EPD equation. (A) The conventional EQD2 formulation results in 5% for every 6 Gy of deviation from the Rx dose when converting the Treatment A 2 Gy/fraction schedule to EQD2. (B) The EQD2 formulation has -20% error at the Rx dose and an additional 5.38% error for every 6 Gy deviation from the Rx dose when converting the Treatment B 3 Gy/fraction schedule to EQD2.

Discussion

In the current era of voxelized dosimetry, prescription-only based BED calculations assuming a uniform dose are no longer sufficient to be considered precision medicine. Effects from variation of dose in the tumor and normal tissue radiobiology must be considered. Presented here is a framework to comprehensively characterize biological effects from absorbed doses in a voxelized manner.

For a delivered therapy, some outlier voxels (e.g. at the junction between different organs or heterogeneous dose distributions from MRT/Brachytherapy) might have deviations in delivered doses of >50%. In aggregate, such as when taking the mean, some of this error may cancel itself out which speaks to the success of the existing models, particularly in parallel organs. However, in serial organs like the spinal cord, the accuracy of dosimetry at the voxel level is critical. Furthermore, because tumor control is dependent on irradiating 100% of tumor cells, having a single voxel undertreated could adversely affect the probability of cure. Paradis et al. alluded to this in the special medical physics consult for reirradiation patients "Evaluation of biological mean dose involves the conversion of each voxel within the structure to biological dose before calculating the mean. This is

problematic in that doses very different from 2 Gy per fraction may skew the mean, making the result difficult to interpret."[6]

The findings from Claim 1 alone do not fully complete the picture like the EPD formulation does. But, the revised EQD2 formulation is valuable in demonstrating that an assumption that the denominator term can be fixed (2+α/β) is false. There is also a question of the choice of parameters as these are typically not well-characterized or from reputable or applicable outcomes sources. Instead, unless proactively chosen otherwise, general parameters e.g. 3 Gy for "normal tissue" and 10 Gy for tumor tissue have been assumed in most cases. In addition, the amount of error introduced depends on model parameterization. Normal tissues with smaller alpha-beta ratios are more affected by errors of the EQD method.

Nevertheless, existing BED models and variations thereof are adequate, as long as they are mechanistically understood and have a clear evidence base (with transparent uncertainty and traceability). A 2013 letter by Fowler[7] recommended against use of EQD for regimens outside of 2 Gy per fraction due to the familiarity of outcomes in the context of this metric. Existing EQD2 might be a reasonable approximation when the assumptions addressed in this article are considered. This has been noted by Withers et al. where uncertainty in the specific modelling parameters for each tissue carries substantial uncertainties.[8] For this reason, caution was advised when employing the EQD model for doses outside of the realm where radiation sensitivity has been adequately characterized.

Furthermore, based on these results, EQD2 may not be the best approach and has possibly added confusion in the field. Therefore, in order to calculate isoeffect or equivalent physical dose, one must simply invert the BED model per the EPD equation to solve for physical dose as a function of BED or SF. Of interest, this inversion approach, assuming an inverse solution exists, should also work for non-conventional LQ model approaches as well since this is in terms of direct biological effect.

As stated by the ICRU Report Committee on "Bioeffect Modeling and Biologically Equivalent Dose Concepts in Radiation Therapy[9], "We recognize the fact that two main schools of bioeffect modeling (EQD2 vs. BED) have developed over time. They use mathematically equivalent formalisms and the difference between them should not be exaggerated. However, differences in concepts and terminologies that may appear similar to the non-expert can cause confusion. We are therefore strongly supportive of recent calls for a consensus on how bioeffect calculations and their results should be reported. It is in everybody's interest to agree on a consistent and standardized terminology as well as recommendations on quantities and units with which authors and users of bioeffect models should strive to comply." The mathematical critique provided by the EPD

explanation challenges the assumption that EQD2 and BED/EPD use equivalent mathematical formalisms. In this way, EPD could guide consolidation of the EQD2 and BED schools of bioeffect modelling.

Current methods of calculating EQD2 assuming uniform prescription dose-based calculations have been successful in their ease of implementation but flawed by the assumptions which make them ungeneralizable. It is advised that EQD2 not be used for voxelized dosimetry unless these assumptions are understood first. Otherwise, the equivalent dose expressions illustrated here can be used correctly with a mathematical justification. In the era of voxelized dosimetry, this article empowers radiation oncology clinics to perform voxelized biological effective dose modelling to correctly evaluate biological effective dose accumulation for common clinical contexts including reirradiation and combination therapies.

References

1. McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol. 2018;64(1):01TR01. Published 2018 Dec 19. doi:10.1088/1361-6560/aaf26a

2. Hoffmann AL, Nahum AE. Fractionation in normal tissues: the (α/β)eff concept can account for dose heterogeneity and volume effects. Phys Med Biol. 2013;58(19):6897-6914. doi:10.1088/0031-9155/58/19/6897

3. Bentzen SM, Dörr W, Gahbauer R, et al. Bioeffect modeling and equieffective dose concepts in radiation oncology--terminology, quantities and units. Radiother Oncol. 2012;105(2):266-268. doi:10.1016/j.radonc.2012.10.006

4. Fowler JF, Dale RG. When Is a "BED" not a "BED"?-When it is an EQD2: In regard to Buyyounouski et al. (Int J Radiat Oncol Biol Phys 2010;76:1297-1304). Int J Radiat Oncol Biol Phys. 2010;78(2):640-641. doi:10.1016/j.ijrobp.2010.04.044

5. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62(740):679-694. doi:10.1259/0007-1285-62-740-679

6. Paradis KC, Mayo C, Owen D, et al. The Special Medical Physics Consult Process for Reirradiation Patients. Adv Radiat Oncol. 2019;4(4):559-565. Published 2019 Jun 8. doi:10.1016/j.adro.2019.05.007

7. Fowler J. Bioeffect Modeling and equieffective dose concepts in radiation oncology: comments on Bentzen et al.'s paper from ICRU in Radiother Oncol 2012;105:266-268. Radiother Oncol. 2013;108(2):354. doi:10.1016/j.radonc.2013.07.009

8. Withers HR, Thames HD Jr, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol. 1983;1(2):187-191. doi:10.1016/s0167-8140(83)80021-8

9. Bentzen SM, Dörr W, Gahbauer R, et al. Bioeffect modeling and equieffective dose concepts in radiation oncology--terminology, quantities and units. Radiother Oncol. 2012;105(2):266-268. doi:10.1016/j.radonc.2012.10.006

Appendix A: Derivation of EQDx

Derivation

The equivalent dose of a treatment in y Gy per fraction in terms of a treatment in x Gy per fraction would be related by the following relationship:

$$- ln(SF_x)/\alpha = - ln(SF_y)/\alpha$$

$$BED_x = BED_y$$

$$n_x d_x (1 + \frac{d_x}{\alpha/\beta}) = n_y d_y (1 + \frac{d_y}{\alpha/\beta})$$

The labelling of EQD is then based on the idea that relative effect term $BED = D \times RE$ can be divided though on both sides. However, this is not the nature of what the original SF equations being set equal to each other was asserting.

$$EQD_x = n_x d_x = n_y d_y \frac{(1+\frac{d_y}{\alpha/\beta})}{(1+\frac{d_x}{\alpha/\beta})} = n_y d_y \frac{(d_y+\alpha/\beta)}{(d_x+\alpha/\beta)}$$

To compare y Gy per fraction to 2 Gy per fraction, this expression reduces to

$$EQD_2 = n_y d_y \frac{(d_y+\alpha/\beta)}{(2\,Gy+\alpha/\beta)}$$

Invalidation of equivalent biological effect

The BED of an EQD for the reference therapy should match the BED of the original therapy (i.e. be invertible). To test this, EQD can be directly substituted into the BED expression.

$$BED = EQD \left(1 + \frac{EQD/n}{\alpha/\beta}\right)$$

Substituting the expression for EQD results in an expression which cannot be reduced.

$$BED = D \frac{(1+\frac{D/n}{\alpha/\beta})}{(1+\frac{d}{\alpha/\beta})} \left(1 + \frac{D\frac{(1+\frac{D/n}{\alpha/\beta})}{(1+\frac{d}{\alpha/\beta})}/n}{\alpha/\beta}\right)$$

Therefore, attempting to invert the EQD operation does not result in the same BED value. Rearranging the terms which appear to cancel out might seem like a possible counter proof. However, this just reproduces the "relative effect" approach (i.e. touching the left hand side) described above.

Appendix B: Derivation and validation of the EPD equation

Derivation

The equivalent dose of treatment y in d_y Gy per fraction in terms of a treatment x in d_x Gy per fraction would be related by the following equation:

$$- ln(SF_x)/\alpha = - ln(SF_y)/\alpha$$

$$BED_x = BED_y$$

$$n_x d_x (1 + \frac{d_x}{\alpha/\beta}) = BED_y$$

$$n_x d_x + (\frac{1}{\alpha/\beta}) n_x d_x^2 = BED_y$$

$$(\frac{n_x}{\alpha/\beta}) d_x^2 + (n_x) d_x + (- BED_y) = 0$$

$$d_x = \frac{-(n_x) + \sqrt{n_x^2 - 4(\frac{n_x}{\alpha/\beta})(-BED_y)}}{2(\frac{n_x}{\alpha/\beta})}$$

$$d_x = \frac{\sqrt{n_x^2 + \frac{4 n_x BED_y}{\alpha/\beta}} - n_x}{\frac{2 n_x}{\alpha/\beta}}$$

$$d_x = \frac{\alpha/\beta}{2 n_x} [\sqrt{n_x^2 + \frac{4 n_x BED_y}{\alpha/\beta}} - n_x]$$

$$d_x = \frac{\alpha/\beta}{2} [\sqrt{1 + \frac{4 BED_y}{n_x(\alpha/\beta)}} - 1]$$

The total dose, i.e. equivalent physical dose (EPD), is then just

$$D_x = n_x d_x$$

$$D_x = n_x \frac{\alpha/\beta}{2} [\sqrt{1 + \frac{4 BED_y}{n_x(\alpha/\beta)}} - 1] = EPD$$

Validation of equivalent biological effect

EPD can be directly substituted into the BED expression and results in an expression which can be reduced to identity.

$$BED = EPD (1 + \frac{EPD/n}{\alpha/\beta})$$

$$BED = n_x \frac{\alpha/\beta}{2} [\sqrt{1 + \frac{4 BED_y}{n_x(\alpha/\beta)}} - 1](1 + \frac{n_x \frac{\alpha/\beta}{2} [\sqrt{1 + \frac{4 BED_y}{n_x(\alpha/\beta)}} - 1]/n}{\alpha/\beta})$$

$$BED = n_x \frac{\alpha/\beta}{2} [\sqrt{1 + \frac{4 BED_y}{n_x(\alpha/\beta)}} - 1](1 + \frac{1}{2} [\sqrt{1 + \frac{4 BED_y}{n_x(\alpha/\beta)}} - 1])$$

$$BED = n_x \frac{\alpha/\beta}{2} [\sqrt{1 + \frac{4 BED_y}{n_x(\alpha/\beta)}} - 1]\frac{1}{2} (2 + [\sqrt{1 + \frac{4 BED_y}{n_x(\alpha/\beta)}} - 1])$$

$$BED = n_x \frac{\alpha/\beta}{4} [\sqrt{1 + \frac{4 BED_y}{n_x(\alpha/\beta)}} - 1][\sqrt{1 + \frac{4 BED_y}{n_x(\alpha/\beta)}} + 1]$$

$$BED = n_x \frac{\alpha/\beta}{4} [1 + \frac{4 BED_y}{n_x(\alpha/\beta)} - 1]$$

$$BED = n_x \frac{\alpha/\beta}{4} [\frac{4 BED_y}{n_x(\alpha/\beta)}]$$

$$BED = BED_y$$

Demonstrated here is the inverse of the BED operation, which moves BED back into physical dose space, correcting for biological effects according to the BED models. The units are the same for EPD and D but different for BED.

Appendix C: Summary of Voxelized Formulas

This section summarizes the formulas used throughout the paper with variables that are consistently defined in simplest terms. Voxelized BED is straightforward as it is calculated by linear-quadratic model dose scaling at each independent dose voxel i using $BED_i = D_i(1 + \frac{D_i/n}{\alpha/\beta})$. Equivalent dose in x Gy per fraction can be calculated for each voxel i. The voxelized EQDx equation implicit from literature is $EQDx_i = \frac{BED_i}{1 + \frac{x}{\alpha/\beta}} = D_i \times \frac{D_i/n + \alpha/\beta}{x + \alpha/\beta}$ where D_i is the absorbed dose at voxel i. The revised EQDx equation implicit from literature per claim 1 is $^{revised}EQDx_i = \frac{BED_i}{1 + \frac{D_i/n_x}{\alpha/\beta}} = D_i \times \frac{D_i/n + \alpha/\beta}{D_i/n_x + \alpha/\beta}$ where n_x is the number of fractions of the reference therapy. The generalizeable voxelized equation per claim 2 has the generalized equivalent physical dose equation $EPDx_i = n_x \frac{\alpha/\beta}{2}[\sqrt{1 + \frac{4BED_i}{n_x(\alpha/\beta)}} - 1]$ where x is the target prescription dose per fraction for the reference therapy, n is the number of fractions. In each of this preceding equations, equivalent dose in 2 Gy per fraction is obtained by substituting "2" in for the x of the voxelized equations